1. Home
  2. NTRB vs PMVP Comparison

NTRB vs PMVP Comparison

Compare NTRB & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$5.66

Market Cap

36.0M

Sector

Health Care

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.36

Market Cap

66.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRB
PMVP
Founded
2016
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
66.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
NTRB
PMVP
Price
$5.66
$1.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.0K
464.4K
Earning Date
05-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,036,651.00
N/A
Revenue This Year
$30.17
N/A
Revenue Next Year
$3,394.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$1.02
52 Week High
$8.63
$1.88

Technical Indicators

Market Signals
Indicator
NTRB
PMVP
Relative Strength Index (RSI) 80.85 57.53
Support Level $4.23 $1.04
Resistance Level $6.41 $1.36
Average True Range (ATR) 0.53 0.07
MACD 0.18 0.00
Stochastic Oscillator 100.00 85.71

Price Performance

Historical Comparison
NTRB
PMVP

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: